ClinicalTrials.gg
CompletedNCT01505127Updated Nov 5, 2013

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

A Phase 3 interventional study of TAK-438 and Lansoprazole in H. Pylori Infection, sponsored by Takeda. Completed at 35 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-11-05.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to confirm the efficacy of triple therapy with TAK-438, Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to triple therapy with Lansoprazole, Amoxicillin and Clarithromycin in H. pylori-positive patients with scarred gastric or duodenal ulcers.

02

Conditions studied

  • H. Pylori Infection

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be H. pylori-positive patients at baseline (Visit 1)
  2. Participants must be endoscopically confirmed to have scarred gastric ulcer or duodenal ulcer at baseline (Visit 1).

    However, if a history of ulcers is confirmed by the medical interview or previous medical record, Participants whose gastric ulcer scar or duodenal ulcer scar has disappeared may be included in the study.

  3. Outpatient (including inpatient for examination)

Exclusion criteria

Exclusion Criteria:

  1. Participants who have received H.pylori eradication treatment
  2. Participants who have either acute upper gastrointestinal bleeding, gastric ulcer [mucosal defect (with white coating including clot adherence) of 3 mm or larger in size], duodenal ulcer [mucosal defect (with white coating including clot adherence) of 3 mm or larger in size], acute gastric mucosal lesion (AGML), or acute duodenal mucosal lesion (ADML) on endoscopic examination at baseline (Visit 1).

    However, participants with gastric erosion or duodenal erosion may be included in the study.

  3. Participants who have received or who are scheduled to undergo surgery which affects gastric acid secretion (ex, resection of upper gastrointestinal tract, vagotomy, etc)
  4. Participants who cannot be treated with medicinal treatment (ex, perforation, pyloric stenosis or large hemorrhage, etc)
  5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
  6. Participants with hepatic or renal impairment receiving treatment with colchicines
  7. Participants who have a history of or allergy to TAK-438 (including its ), PPIs, penicillin antibiotics, macrolide antibiotics, or antitrichomonal agents
  8. Participants with infectious mononucleosis
  9. Participants with an organic disease of the brain or spinal cord
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
650 participants (actual)

Study arms

  • Experimental
    TAK-438 20 mg BID

    TAK-438 20 mg, tablets, orally, twice daily for 1 week Lansoprazole placebo-matching capsules, orally, twice daily for 1 week Amoxicillin 750 mg, capsules, orally, twice daily for 1 week Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week

    Drug: TAK-438 · Drug: Amoxicillin · Drug: Clarithromycin

  • Experimental
    Lansoprazole 30 mg BID

    TAK-438 placebo-matching tablets, orally, twice daily for 1 week Lansoprazole 30 mg, capsules, orally, twice daily for 1 week Amoxicillin 750 mg, capsules, orally, twice daily for 1 week Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week

    Drug: Lansoprazole · Drug: Amoxicillin · Drug: Clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. H. pylori eradication rate 4 weeks after completion of first-line therapy

    The participants are judged to be H. pylori-negative or H. pylori-positive based on the 13C-Urea Breath Test.

    Time frame: 4-weeks post-dose (first-line therapy)

Secondary outcomes

  1. H. pylori eradication rate 4 weeks after completion of second-line therapy

    Time frame: 4-weeks post-dose (second-line therapy)

07

Study locations

35 sites
  • Abiko-shi, Chiba, Japan
  • Kashiwa-shi, Chiba, Japan
  • Fukui-shi, Fukui, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Ishikari-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Kobe-shi, Hyogo, Japan
  • Nishinomiya-shi, Hyogo, Japan
  • Marugame-shi, Kagawa, Japan
  • Takamatsu-shi, Kagawa, Japan
  • Kagoshima-shi, Kagoshima, Japan
  • Ebina-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Yatsushiro-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Oita-shi, Oita, Japan
  • Hirakata-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Sakai-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Takatsuki-shi, Osaka, Japan
  • Toyonaka-shi, Osaka, Japan
  • Saga-shi, Saga, Japan
  • Kumagaya-shi, Saitama, Japan
  • Tokorozawa-shi, Saitama, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Adachi-ku, Tokyo, Japan
  • Chiyoda-ku, Tokyo, Japan
  • Hachioji-shi, Tokyo, Japan
  • Kokubunji-shi, Tokyo, Japan
  • Nishi-tokyo-shi, Tokyo, Japan
  • Oota-ku, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shibuya-ku, Tokyo, Japan
08

References and documents

Publications

  • Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304. Epub 2016 Mar 2. PubMed 26935876 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2011
First posted
Jan 6, 2012
Start
Jan 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Nov 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01505127
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 6, 2012
Start date
Jan 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Nov 5, 2013

Study contacts

Senior Manager
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vonoprazan · Lansoprazole

Start the discussion